Ovid Therapeutics

OVIDPre-clinical

Ovid Therapeutics is a clinical-stage biopharmaceutical company with a mission to transform the lives of patients with rare neurological disorders. The company leverages its expertise in brain biology to develop targeted therapies for conditions like Angelman syndrome, CDKL5 deficiency disorder, and developmental and epileptic encephalopathies. Ovid's strategy involves both internal development and strategic partnerships to advance its pipeline. The company is publicly traded and has established collaborations with leading research institutions and biotech partners.

Market Cap

$186.6M

Employees

20-50

Focus

Biotech

OVID · Stock Price

USD 2.620.60 (-18.63%)

Historical price data

AI Company Overview

Technology Platform

Focus on developing novel small molecules and gene therapies targeting specific pathways in rare neurological disorders, with expertise in brain biology and CNS delivery.

Opportunities

Major near-term opportunity is the potential approval and commercialization of soticlestat by Takeda, triggering milestone payments and establishing a royalty stream.

Long-term growth depends on successfully advancing its internal Angelman syndrome programs (OV350, OV882) into and through clinical trials, addressing a completely unserved market.

Risk Factors

High risk of clinical failure for all preclinical/internal programs.

Dependence on Takeda for the success of the most advanced asset.

Need to raise additional capital, leading to potential shareholder dilution.

Intense and growing competition in the rare neurology space, particularly for Angelman syndrome.

Competitive Landscape

Faces competition in Angelman syndrome from companies like Roche/Genentech, Ultragenyx, and GeneTx developing various modalities. In epileptic encephalopathies, competes with approved therapies (Epidiolex, Fintepla) and other late-stage candidates. Differentiation hinges on novel mechanisms and potential for disease modification in Angelman syndrome.